PubRank

Ann G Zauber

Author PubWeight™ 112.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010 13.27
2 Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006 7.62
3 Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014 6.54
4 Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006 6.15
5 Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006 4.57
6 Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006 3.21
7 Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010 3.05
8 Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006 2.68
9 How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006 2.68
10 A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2008 2.56
11 Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut 2013 2.50
12 Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2008 2.47
13 Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009 2.46
14 Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev 2012 2.39
15 Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med 2014 2.31
16 Statin use and the risk of breast and prostate cancer. Epidemiology 2002 2.15
17 Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009 1.96
18 Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009 1.89
19 At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer 2009 1.88
20 National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004 1.83
21 A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 2011 1.77
22 The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002 1.73
23 Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making 2011 1.71
24 C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila) 2011 1.57
25 Colonoscopy surveillance after polypectomy and colorectal cancer resection. Am Fam Physician 2008 1.52
26 Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care 2008 1.37
27 Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med 2014 1.32
28 Flat adenomas in the National Polyp Study: is there increased risk for high-grade dysplasia initially or during surveillance? Clin Gastroenterol Hepatol 2004 1.32
29 Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev 2007 1.25
30 Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst 2012 1.25
31 Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010 1.24
32 Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 2009 1.23
33 Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2010 1.20
34 Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology 2012 1.15
35 Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 2008 1.14
36 Phytoestrogen consumption and endometrial cancer risk: a population-based case-control study in New Jersey. Cancer Causes Control 2009 1.13
37 High-quality colonoscopies must be an integral part of screening and surveillance programs. Gastroenterology 2006 1.12
38 Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med 2016 1.10
39 Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. AJR Am J Roentgenol 2011 1.07
40 Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 2002 1.00
41 Adherence to the dietary guidelines for Americans and endometrial cancer risk. Cancer Causes Control 2010 0.98
42 Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009 0.97
43 The economic impact of a patient navigator program to increase screening colonoscopy. Cancer 2012 0.89
44 Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 2005 0.88
45 Changes in risk factors and increases in screening contribute to the decline in colorectal cancer mortality, 1975 to 2000. Gastroenterology 2010 0.86
46 Coffee and tea consumption and endometrial cancer risk in a population-based study in New Jersey. Cancer Causes Control 2010 0.83
47 Derivation of background mortality by smoking and obesity in cancer simulation models. Med Decis Making 2012 0.80
48 Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 2013 0.80
49 Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making 2012 0.79
50 The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila) 2011 0.79
51 Incidence reduction following colonoscopic polypectomy. Am J Gastroenterol 2011 0.78
52 Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 2011 0.78
53 United States Preventive Services Task Force recommendations: age to end screening misunderstood. Dis Colon Rectum 2010 0.78
54 Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. J Med Screen 2013 0.78
55 Simulation of colorectal cancer screening: what we do and do not know and does it matter. Best Pract Res Clin Gastroenterol 2010 0.77
56 On finding flat adenomas: is the search worth the gain? Gastroenterology 2002 0.77
57 Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. Med Care 2015 0.76
58 Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer Prev Res (Phila) 2009 0.76
59 Quality control for flexible sigmoidoscopy: which polyps count? Gastroenterology 2004 0.76
60 Extracolonic findings from CTC: balancing risks and benefits. AJR Am J Roentgenol 2009 0.75
61 Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy. Epidemiol Rev 2017 0.75
62 Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing. J Clin Gastroenterol 2017 0.75
63 A restricted look at CRC screening: not considering annual stool testing as an option. Am J Manag Care 2016 0.75